Produto adicionado correctamente ao carrinho.

discount label
H-SNTSESF-NH2
Ver 3D

Biosynth logo

H-SNTSESF-NH2

Ref. 3D-PP48195

Tamanho indefinidoA consultar
Entrega estimada em Estados Unidos, Terça-feira 10 de Dezembro de 2024

Informação sobre produto

Nome:
H-SNTSESF-NH2
Descrição:

Peptide H-SNTSESF-NH2 is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SNTSESF-NH2 include the following: Nanomedicine strategies for heating"cold" ovarian cancer (OC): next evolution in immunotherapy of OC Y Yang, T Zhao, Q Chen, Y Li, Z Xiao - Advanced , 2022 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/advs.202202797 A Bispecific Peptide-Polymer Conjugate Bridging Target-Effector Cells to Enhance Immunotherapy W Zhang, D Li, X Xu, Y Chen, X Shi - Advanced , 2023 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/adhm.202202977 Development of inhibitors of the programmed cell death-1/programmed cell death-ligand 1 signaling pathway T Wang, X Wu, C Guo, K Zhang, J Xu - Journal of medicinal , 2018 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.8b00990 The Synthesis and Anti-tumour Properties of Poly Ethoxy Ethyl Glycinamide (PEE-G) Scaffolds with Multiple PD-1 Peptides Attached R Shrestha , EV Petley, KJ Farrand - , 2020 - Wiley Online Libraryhttps://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.202000221 The synthesis of potential drug candidates based on the PEE-G dendrimer scaffold R Shrestha - 2019 - openaccess.wgtn.ac.nzhttps://openaccess.wgtn.ac.nz/articles/thesis/The_synthesis_of_potential_drug_candidates_based_on_the_PEE-G_dendrimer_scaffold/22777214 PD-1/PD-L1 inhibitors for immuno-oncology: from antibodies to small molecules Q Geng, P Jiao, P Jin, G Su, J Dong - Current Pharmaceutical , 2017 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cpd/2017/00000023/00000039/art00008 PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy PG Sasikumar, NS Sudarshan, S Adurthi - Communications , 2021 - nature.comhttps://www.nature.com/articles/s42003-021-02191-1 [68Ga]Ga-AUNP-12 PET imaging to assess the PD-L1 status in preclinical and first-in-human study M Zhou, S Xiang, Y Zhao , Y Tang , J Yang, X Yin - European Journal of , 2024 - Springerhttps://link.springer.com/article/10.1007/s00259-023-06447-2 A Plant Virus Nanoparticle Toolbox to Combat Cancer K Hefferon, M Shahgolzari , A Yavari - pharmafocusasia.comhttps://www.pharmafocusasia.com/research-development/plant-virus-nanoparticle-toolbox Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor J Liu, G Wang, L Liu, R Wu, Y Wu, C Fang, X Zhou - Scientific reports, 2019 - nature.comhttps://www.nature.com/articles/s41598-019-54231-w Targeted drug delivery system for ovarian cancer microenvironment: Improving the effects of immunotherapy H Peng, X He, Q Wang - Frontiers in Immunology, 2022 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2022.1035997/full Emerging Trends in Nano-Driven Immunotherapy for Treatment of Cancer G Kandasamy, Y Karuppasamy , UM Krishnan - Vaccines, 2023 - mdpi.comhttps://www.mdpi.com/2076-393X/11/2/458 Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy E Khatoon, D Parama , A Kumar , MS Alqahtani - Life Sciences, 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0024320522005276 VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses C Wu, X Cao , X Zhang - RSC Medicinal Chemistry, 2021 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2021/md/d1md00185j CA-170-a potent small-molecule PD-L1 inhibitor or not? B Musielak, J Kocik , L Skalniak , K Magiera-Mularz - Molecules, 2019 - mdpi.comhttps://www.mdpi.com/1420-3049/24/15/2804 Virus-like particles: a self-assembled toolbox for cancer therapy A Shahrivarkevishahi , LM Hagge, OR Brohlin - Materials Today , 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2468519422000374 Materials Today Chemistry A Shahrivarkevishahi , LM Hagge, OR Brohlin - Materials , 2022 - labs.utdallas.eduhttps://labs.utdallas.edu/gassensmith/files/2022/03/1-s2.0-S2468519422000374-main.pdf Chemically Tuned Virus Like Particles: From Cancer Therapy to Targeted Delivery A Shahrivarkevishahi - 2021 - utd-ir.tdl.orghttps://utd-ir.tdl.org/items/2c22f8e6-d588-43ac-95a3-5f2fced7a7e8 Plant viral nanoparticle conjugated with anti-PD-1 peptide for ovarian cancer immunotherapy A Gautam, V Beiss, C Wang , L Wang - International Journal of , 2021 - mdpi.comhttps://www.mdpi.com/1422-0067/22/18/9733

Aviso:
Os nossos productos estão destinados exclusivamente para uso em laboratório. Para qualquer outra aplicação, por favor entre em contacto.
Marca:
Biosynth
Armazenamento a longo prazo:
Notas:

Propriedades químicas

MDL:
Ponto de fusão:
Ponto de ebulição:
Ponto de inflamação:
Densidade:
Concentração:
EINECS:
Merck:
Código HS:

Informação sobre riscos

Número ONU:
EQ:
Classe:
Frases H:
Frases P:
Proibido de voar:
Informação sobre riscos:
Grupo de Embalagem:
LQ:

Consulta técnica sobre: 3D-PP48195 H-SNTSESF-NH2

Por favor, utilize o carrinho para solicitar um orçamento ou uma encomenda

Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.

* Campos obrigatórios
Bem-vindo à CymitQuimica!Usamos cookies para melhorar sua visita. Não incluímos publicidade.

Consulte a nossa Política de Cookies para mais detalhes ou ajuste suas preferências em "Configurar".